Prevention of allergic rhinitis by aldose reductase inhibition in a murine model.

Umesh C S Yadav, Rakesh Mishra, Leopoldo Aguilera-Aguirre, Sanjiv Sur, Istvan Bolodgh, Kota Ramana, Satish K. Srivatsava

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Allergic rhinitis, one of the most common atopic diseases, is known to be elicited by Th2 cytokine-mediated inflammatory response. We have shown earlier that a polyol pathway enzyme aldose reductase (AR) regulates airway inflammation; however its role in allergic rhinitis is not known. We have investigated the role of AR in mediating pathological symptoms associated with allergic rhinitis in mice. The wild-type (WT) mice treated without or with AR inhibitor and AR knock out (AR(-/-)) mice were sensitized by two intraperitoneal injections of ragweed pollen extract (RWE) with adjuvant alum on days 0 and 4 followed by challenge on day 11 and/or 18 and 25. The allergic rhinitis symptoms were assessed by monitoring the nasal scratch, mast cell degranulation and release of tryptase in nasal lavage, infiltration of inflammatory cells, production of inflammatory cytokines and nasal epithelium remodeling. Sensitization and challenge of mice with RWE produced robust and reproducible pathological symptoms of allergic rhinitis as compared to control mice. AR inhibitor, fidarestat administered mice showed markedly reduced early phase response to allergen exposure such as nasal scratches, mast cells degranulation and release of tryptase in the nasal passage as well as late phase response such as inflammatory cell infiltration and release of Th2 type cytokines and nasal epithelial remodeling. Further, prevention of these events in AR(-/-)) mice suggests the role of AR in the mediation of allergic rhinitis. These results indicate an important role of AR in the mediation of RWE-induced allergic rhinitis in mice and prevention by AR inhibitor, fidarestat offers a novel therapeutic approach to ameliorate allergic rhinitis.

Original languageEnglish (US)
Pages (from-to)178-186
Number of pages9
JournalInflammation & allergy drug targets
Volume12
Issue number3
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Aldehyde Reductase
Nose
Cell Degranulation
Tryptases
Cytokines
Mast Cells
Nasal Lavage
Allergic Rhinitis
Nasal Mucosa
Intraperitoneal Injections
Allergens
Inflammation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Yadav, U. C. S., Mishra, R., Aguilera-Aguirre, L., Sur, S., Bolodgh, I., Ramana, K., & Srivatsava, S. K. (2013). Prevention of allergic rhinitis by aldose reductase inhibition in a murine model. Inflammation & allergy drug targets, 12(3), 178-186.

Prevention of allergic rhinitis by aldose reductase inhibition in a murine model. / Yadav, Umesh C S; Mishra, Rakesh; Aguilera-Aguirre, Leopoldo; Sur, Sanjiv; Bolodgh, Istvan; Ramana, Kota; Srivatsava, Satish K.

In: Inflammation & allergy drug targets, Vol. 12, No. 3, 06.2013, p. 178-186.

Research output: Contribution to journalArticle

Yadav, UCS, Mishra, R, Aguilera-Aguirre, L, Sur, S, Bolodgh, I, Ramana, K & Srivatsava, SK 2013, 'Prevention of allergic rhinitis by aldose reductase inhibition in a murine model.', Inflammation & allergy drug targets, vol. 12, no. 3, pp. 178-186.
Yadav UCS, Mishra R, Aguilera-Aguirre L, Sur S, Bolodgh I, Ramana K et al. Prevention of allergic rhinitis by aldose reductase inhibition in a murine model. Inflammation & allergy drug targets. 2013 Jun;12(3):178-186.
Yadav, Umesh C S ; Mishra, Rakesh ; Aguilera-Aguirre, Leopoldo ; Sur, Sanjiv ; Bolodgh, Istvan ; Ramana, Kota ; Srivatsava, Satish K. / Prevention of allergic rhinitis by aldose reductase inhibition in a murine model. In: Inflammation & allergy drug targets. 2013 ; Vol. 12, No. 3. pp. 178-186.
@article{a4dfd8f20735420fb766db32fd7ba516,
title = "Prevention of allergic rhinitis by aldose reductase inhibition in a murine model.",
abstract = "Allergic rhinitis, one of the most common atopic diseases, is known to be elicited by Th2 cytokine-mediated inflammatory response. We have shown earlier that a polyol pathway enzyme aldose reductase (AR) regulates airway inflammation; however its role in allergic rhinitis is not known. We have investigated the role of AR in mediating pathological symptoms associated with allergic rhinitis in mice. The wild-type (WT) mice treated without or with AR inhibitor and AR knock out (AR(-/-)) mice were sensitized by two intraperitoneal injections of ragweed pollen extract (RWE) with adjuvant alum on days 0 and 4 followed by challenge on day 11 and/or 18 and 25. The allergic rhinitis symptoms were assessed by monitoring the nasal scratch, mast cell degranulation and release of tryptase in nasal lavage, infiltration of inflammatory cells, production of inflammatory cytokines and nasal epithelium remodeling. Sensitization and challenge of mice with RWE produced robust and reproducible pathological symptoms of allergic rhinitis as compared to control mice. AR inhibitor, fidarestat administered mice showed markedly reduced early phase response to allergen exposure such as nasal scratches, mast cells degranulation and release of tryptase in the nasal passage as well as late phase response such as inflammatory cell infiltration and release of Th2 type cytokines and nasal epithelial remodeling. Further, prevention of these events in AR(-/-)) mice suggests the role of AR in the mediation of allergic rhinitis. These results indicate an important role of AR in the mediation of RWE-induced allergic rhinitis in mice and prevention by AR inhibitor, fidarestat offers a novel therapeutic approach to ameliorate allergic rhinitis.",
author = "Yadav, {Umesh C S} and Rakesh Mishra and Leopoldo Aguilera-Aguirre and Sanjiv Sur and Istvan Bolodgh and Kota Ramana and Srivatsava, {Satish K.}",
year = "2013",
month = "6",
language = "English (US)",
volume = "12",
pages = "178--186",
journal = "Current Drug Targets: Inflammation and Allergy",
issn = "1871-5281",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Prevention of allergic rhinitis by aldose reductase inhibition in a murine model.

AU - Yadav, Umesh C S

AU - Mishra, Rakesh

AU - Aguilera-Aguirre, Leopoldo

AU - Sur, Sanjiv

AU - Bolodgh, Istvan

AU - Ramana, Kota

AU - Srivatsava, Satish K.

PY - 2013/6

Y1 - 2013/6

N2 - Allergic rhinitis, one of the most common atopic diseases, is known to be elicited by Th2 cytokine-mediated inflammatory response. We have shown earlier that a polyol pathway enzyme aldose reductase (AR) regulates airway inflammation; however its role in allergic rhinitis is not known. We have investigated the role of AR in mediating pathological symptoms associated with allergic rhinitis in mice. The wild-type (WT) mice treated without or with AR inhibitor and AR knock out (AR(-/-)) mice were sensitized by two intraperitoneal injections of ragweed pollen extract (RWE) with adjuvant alum on days 0 and 4 followed by challenge on day 11 and/or 18 and 25. The allergic rhinitis symptoms were assessed by monitoring the nasal scratch, mast cell degranulation and release of tryptase in nasal lavage, infiltration of inflammatory cells, production of inflammatory cytokines and nasal epithelium remodeling. Sensitization and challenge of mice with RWE produced robust and reproducible pathological symptoms of allergic rhinitis as compared to control mice. AR inhibitor, fidarestat administered mice showed markedly reduced early phase response to allergen exposure such as nasal scratches, mast cells degranulation and release of tryptase in the nasal passage as well as late phase response such as inflammatory cell infiltration and release of Th2 type cytokines and nasal epithelial remodeling. Further, prevention of these events in AR(-/-)) mice suggests the role of AR in the mediation of allergic rhinitis. These results indicate an important role of AR in the mediation of RWE-induced allergic rhinitis in mice and prevention by AR inhibitor, fidarestat offers a novel therapeutic approach to ameliorate allergic rhinitis.

AB - Allergic rhinitis, one of the most common atopic diseases, is known to be elicited by Th2 cytokine-mediated inflammatory response. We have shown earlier that a polyol pathway enzyme aldose reductase (AR) regulates airway inflammation; however its role in allergic rhinitis is not known. We have investigated the role of AR in mediating pathological symptoms associated with allergic rhinitis in mice. The wild-type (WT) mice treated without or with AR inhibitor and AR knock out (AR(-/-)) mice were sensitized by two intraperitoneal injections of ragweed pollen extract (RWE) with adjuvant alum on days 0 and 4 followed by challenge on day 11 and/or 18 and 25. The allergic rhinitis symptoms were assessed by monitoring the nasal scratch, mast cell degranulation and release of tryptase in nasal lavage, infiltration of inflammatory cells, production of inflammatory cytokines and nasal epithelium remodeling. Sensitization and challenge of mice with RWE produced robust and reproducible pathological symptoms of allergic rhinitis as compared to control mice. AR inhibitor, fidarestat administered mice showed markedly reduced early phase response to allergen exposure such as nasal scratches, mast cells degranulation and release of tryptase in the nasal passage as well as late phase response such as inflammatory cell infiltration and release of Th2 type cytokines and nasal epithelial remodeling. Further, prevention of these events in AR(-/-)) mice suggests the role of AR in the mediation of allergic rhinitis. These results indicate an important role of AR in the mediation of RWE-induced allergic rhinitis in mice and prevention by AR inhibitor, fidarestat offers a novel therapeutic approach to ameliorate allergic rhinitis.

UR - http://www.scopus.com/inward/record.url?scp=84897122810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897122810&partnerID=8YFLogxK

M3 - Article

C2 - 23360251

AN - SCOPUS:84897122810

VL - 12

SP - 178

EP - 186

JO - Current Drug Targets: Inflammation and Allergy

JF - Current Drug Targets: Inflammation and Allergy

SN - 1871-5281

IS - 3

ER -